Eating and weight related cognitions in people with schizophrenia: A case control study

Clinical Practice and Epidemiology in Mental Health

Volumn 2, Issue , 2006, Pages

  Khazaal, Yasser ^a   Frésard, Emmanuelle ^a   Zimmermann, Grégoire ^b,c   Trombert, Nathalie Morinière ^d   Pomini, Valentino ^a   Grasset, François ^a   Borgeat, François ^a   Zullino, Daniele ^e  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF FRIBOURG   (Switzerland)

^d Fondation Edith Seltzer   (France)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ATORVASTATIN; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLORAZEPATE; CLOZAPINE; ESOMEPRAZOLE; FLURAZEPAM; LORAZEPAM; OLANZAPINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE;

ADULT; ANOREXIA; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; FEAR; FEEDING BEHAVIOR; FEMALE; HUMAN; MALE; OBESITY; OUTPATIENT; PATIENT ATTITUDE; QUESTIONNAIRE; RATING SCALE; SCHIZOPHRENIA; SELF CONTROL; SELF ESTEEM; SEX DIFFERENCE; SIDE EFFECT; WEIGHT GAIN;

EID: 33751009655     PISSN: 17450179     EISSN: None     Source Type: Journal    
DOI: 10.1186/1745-0179-2-29     Document Type: Article

References (35)

1. Baptista T: Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999, 100:3-16.
2. Zimmermann U, Kraus T, Himmerich H, Schuld A. Pollmacher T: Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003, 37:193-220.
3. Baptista T, Kin NM, Beaulieu S, de Baptista EA: Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002, 35:205-219.
4. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ: The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999, 60:215-220.
5. Stedman T, Welham J: The distribution of adipose tissue in female in-patients receiving psychotropic drugs. Br J Psychiatry 1993, 162:249-250.
6. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999, 60:358-363.
7. Newcomer JW: Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004, 65 Suppl 18:36-46.
8. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR: Development of a brief measure to assess quality of life in obesity. Obes Res 2001, 9:102-111.
9. Stanton JM: Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995, 21:463-472.
10. Nasrallah H: A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003, 28 Suppl 1:83-96.
11. Jones B, Basson BP, Walker DJ, Crawford AM, Kinon BJ: Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001, 62 Suppl 2:41-44.
12. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000, 157:975-981.
13. Beasley CM Jr., Tollefson GD, Tran PV: Safety of olanzapine. J Clin Psychiatry 1997, 58 Suppl 10: 13-17.
14. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW: Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995, 5:437-440.
15. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001, 62:231-238.
16. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J: Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998, 3:76-80.
17. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M: Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992, 149:68-72.
18. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A: Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002, 159:1055-1057.
19. Aquila R. Management of weight gain in patients with schizophrenia. J Clin Psychiatry 2002, 63 Suppl 4:33-36.
20. Theisen FM, Linden A, Konig IR, Martin M, Remschmidt H, Hebebrand J: Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003, 110:111-121.
21. Mizes JS, Klesges RC: Validity, reliability, and factor structure of the Anorectic Cognitions Questionnaire. Addict Behav 1989, 14:589-594.
22. Westenhoefer J: Dietary restraint and disinhibition: is restraint a homogeneous construct? Appetite 1991, 16:45-55.
23. Ruderman AJ: Dietary restraint: a theoretical and empirical review. Psychol Bull 1986, 99:247-262.
24. Fedoroff I, Polivy J, Herman CP: The specificity of restrained versus unrestrained eaters' responses to food cues: general desire to eat, or craving for the cued food? Appetite 2003, 41:7-13.
25. Polivy J, Herman CP: Dieting and binging. A causal analysis. Am Psychol 1985, 40:193-201.
26. Cargill BR, Clark MM, Pera V, Niaura RS, Abrams DB: Binge eating, body image, depression, and self-efficacy in an obese clinical population. Obes Res 1999, 7:379-386.
27. Hsu LK, Mulliken B, McDonagh B, Krupa DS, Rand W, Fairburn CG, Rolls B, McCrory MA, Saltzman E, Shikora S, Dwyer J, Roberts S: Binge eating disorder in extreme obesity. Int J Obes Relat Metab Disord 2002, 26:1398-1403.
28. Sherwood NE, Jeffery RW, Wing RR: Binge status as a predictor of weight loss treatment outcome. Int J Obes Relat Metab Disord 1999, 23:485-493.
29. Agras WS, Telch CF, Arnow B, Eldredge K, Marnell M: One-year follow-up of cognitive-behavioral therapy for obese individuals with binge eating disorder. J Consult Clin Psychol 1997, 65:343-347.
30. Mizes JS, Christiano B, Madison J, Post G, Seime R, Vamado P: Development of the mizes anorectic cognitions questionnaire-revised: psychometric properties and factor structure in a large sample of eating disorder patients. Int J Eat Disord 2000, 28:415-421.
31. Mizes JS, Sloan DM: An empirical analysis of eating disorder, not otherwise specified: preliminary support for a distinct subgroup. Int J Eat Disord 1998, 23:233-242.
32. Garner DM, Olmsted MP: Scoring the eating disorder inventory. Am J Psychiatry 1986, 143:680-681.
33. Laessle RG, Tuschl RJ, Kotthaus BC, Pirke KM: A comparison of the validity of three scales for the assessment of dietary restraint. J Abnorm Psychol 1989, 98:504-507.
34. Osman A, Chiros CE, Gutierrez PM, Kopper BA, Barrios FX: Factor structure and psychometric properties of the brief Mizes Anorectic Cognitions questionnaire. J Clin Psychol 2001, 57:785-799.
35. Fallon AE, Rozin P: Sex differences in perceptions of desirable body shape. J Abnorm Psychol 1985, 94:102-105.